

41. A method of enhancing the use dependency of a calcium channel blocking 1,4-dihydropyridine compound selected from nifedipine and nicardipine, compared with a non-deuterated nifedipine and nicardipine, respectively, whereby one or more hydrogen atoms of one or both of the methyl groups in the 2 and 6 positions are replaced with a deuterium atom.

B / 42. The method of claim 41 wherein the dihydropyridine compound is characterized in that all hydrogen atoms of the methyl groups in the 2 and 6 positions are replaced with deuterium atoms.

43. A method of modifying the dose-response relationship of a calcium channel blocking 1,4-dihydropyridine compound selected from nifedipine and nicardipine, compared with a non-deuterated nifedipine and nicardipine, respectively, whereby one or more hydrogen atoms of one or both of the methyl groups in the 2 and 6 positions are replaced with a deuterium atom.

44. The method of claim 43 wherein the channel blocking 1,4-dihydropyridine compound is characterized in that all hydrogen atoms of the methyl groups in the 2 and 6 positions are replaced with deuterium atoms.

Respectfully submitted,
BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 

Charles H. Jew
Registration No. 34,192

P.O. Box 1404
Alexandria, Virginia 22313-1404
(650)622-2300

Date: November 13, 2001